ALPHA PROGRAM
DEAD

Serial Number

76476956

Owner

Unifund Corporation

First Use Date

Jan 1, 2002

Filing Date

Dec 19, 2002

Add to watchlist:

No watchlists yet
View on USPTO

ALPHA PROGRAM Trademark

Serial Number: 76476956 • Registration: 2764079

ALPHA PROGRAM is a trademark filed by Unifund Corporation on December 19, 2002. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Unifund Corporation (23 trademarks)

10625 Techwoods Circle
Cincinnati, OH 45242

Entity Type: 03

UNIFUND CORPORATION LIMITED (5 trademarks)

BRUSHFIELD STREET
LONDON E1 6EU , GB

Entity Type: 13

Sassover; Nathan (5 trademarks)

Los Angeles, CA 90046

Entity Type: 01

Trademark Details

Filing Date

December 19, 2002

Registration Date

September 16, 2003

First Use Anywhere

January 1, 2002

First Use in Commerce

January 1, 2002

Published for Opposition

June 24, 2003

Cancellation Date

April 18, 2014

Goods & Services

Medicinal preparations in the form of powders, capsules, tablets, salves, ointments, oils, solutions, and drops all used as a neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer for the elimination of anxiety and hyperactivity, mitigation of panic symptomology, reduction of fatigue, improvement of self-confidence and self-esteem, elimination of the need for anti-depressants, cognitive enhancement, improvement of aerobic endurance and performance and weight-training capacity, improvement of blood circulation, reduction of blood pressure and hypertension, improvement of sexual performance and libido, reduction of hormonal imbalance in menopausal and post-menopausal women, improvement of visual and auditory acuity, improvement of physical agility and muscle flexibility, improvement of social interaction skills, promotion of relaxation response and mitigation of chronic sleep pattern disorders such as insomnia and other chronic sleep disorders, reduction of arthritic pain and swelling, enhancement of immune system functioning, improvement of the metabolism, relief from constipation, improvement of skin tone, mitigation of "jet lag," and reduction in caffeine dependence; and the treatment of a broad spectrum of conditions and pathologies, namely, age-related and neuro-degenerative conditions and pathologies, nerve diseases, general anxiety disorder, depression, neurosis, neurasthenia, obsessive-compulsive disorder, chronic sleep disorder, chronic fatigue syndrome, digestive diseases, chronic constipation, hypertension, osteoarthritis pain and swelling, and human sexual desire disorder

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Apr 18, 2014 CAEX
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 8, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 8, 2011 REAP
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Mar 25, 2010 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 23, 2010 APRE
TEAS SECTION 8 & 15 RECEIVED
Mar 3, 2010 E815
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 3, 2010 ASGN
CORRECTION UNDER SECTION 7 - PROCESSED
Feb 11, 2005 COC.
CORRECTION UNDER SECTION 7 - PROCESSED
Nov 27, 2004 COC.
PAPER RECEIVED
Aug 24, 2004 MAIL
POST REGISTRATION ACTION MAILED - SEC. 7
Jun 17, 2004 PRAM
REGISTERED-PRINCIPAL REGISTER
Sep 16, 2003 R.PR
PUBLISHED FOR OPPOSITION
Jun 24, 2003 PUBO
NOTICE OF PUBLICATION
Jun 4, 2003 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 17, 2003 CNSA
EXAMINERS AMENDMENT MAILED
Apr 16, 2003 CNEA
NON-FINAL ACTION MAILED
Mar 26, 2003 CNRT
ASSIGNED TO EXAMINER
Mar 20, 2003 DOCK